What is the recommended antiviral and supportive treatment for influenza in adults and children, including dosing and considerations for high‑risk patients?

Influenza Treatment

Oseltamivir is the first-line antiviral for treating influenza in both adults and children, and should be initiated as soon as possible—ideally within 48 hours of symptom onset—for any hospitalized patient, severely ill patient, or high-risk patient, regardless of vaccination status. 1, 2, 3

Who Should Receive Antiviral Treatment

Mandatory Treatment (Start Immediately)

• Any hospitalized child or adult with suspected or confirmed influenza, regardless of symptom duration 3
• Severe, complicated, or progressive illness attributable to influenza 1, 3
• High-risk patients (Table below) with influenza of any severity 1

Consider Treatment For

• Otherwise healthy children whose siblings are <6 months old or have high-risk conditions 1
• Patients presenting >48 hours after symptom onset if they have moderate-to-severe or progressive disease 1

High-Risk Groups Requiring Treatment

• Children <2 years (especially <6 months)
• Adults ≥65 years
• Pregnant and postpartum women (up to 2 weeks after delivery)
• Immunocompromised patients
• Chronic medical conditions: asthma, COPD, cardiac disease, diabetes, renal dysfunction, neurologic disorders, hemoglobinopathies
• Morbid obesity (BMI ≥40)
• Residents of nursing homes or chronic care facilities 1, 2

Antiviral Medications and Dosing

Oseltamivir (First-Line Agent) 1, 2

Adults:

• Treatment: 75 mg twice daily × 5 days
• Prophylaxis: 75 mg once daily × 10 days

Children ≥12 months (weight-based):

• <15 kg: 30 mg twice daily (treatment) / 30 mg once daily (prophylaxis)
• 15-23 kg: 45 mg twice daily / 45 mg once daily
• 23-40 kg: 60 mg twice daily / 60 mg once daily

• 40 kg: 75 mg twice daily / 75 mg once daily

Infants 9-11 months:

• 3.5 mg/kg per dose twice daily (treatment) / once daily (prophylaxis)

Term infants 0-8 months:

• 3 mg/kg per dose twice daily (treatment)
• 3 mg/kg once daily for prophylaxis (only for 3-8 months; not recommended <3 months unless critical) 1, 2

Preterm infants (by postmenstrual age): 2

• <38 weeks: 1.0 mg/kg twice daily
• 38-40 weeks: 1.5 mg/kg twice daily

• 40 weeks: 3.0 mg/kg twice daily

Renal impairment: Reduce to 75 mg once daily for creatinine clearance 10-30 mL/min 1

Zanamivir (Alternative Agent) 1, 2

Adults and children ≥7 years (treatment) or ≥5 years (prophylaxis):

• Treatment: 10 mg (two 5-mg inhalations) twice daily × 5 days
• Prophylaxis: 10 mg once daily × 10 days

Contraindications: Not recommended for patients with asthma or COPD due to bronchospasm risk 2

Peramivir (IV Option) 2

Adults:

• Single 600 mg IV infusion over 15-30 minutes

Children 2-12 years:

• Single 12 mg/kg dose (max 600 mg) IV over 15-30 minutes

Children 13-17 years:

• Single 600 mg IV over 15-30 minutes

Baloxavir (Newer Agent) 2, 4, 5

Patients ≥12 years and >40 kg:

• 40-80 kg: Single 40 mg oral dose
• ≥80 kg: Single 80 mg oral dose

Note: WHO 2024 guidelines conditionally recommend baloxavir for high-risk non-severe cases within 2 days of symptom onset, but it is NOT recommended for non-severe cases without risk factors 4, 5

Critical Timing Considerations

Start treatment immediately—do not wait for test results if influenza is suspected clinically during flu season 1. Earlier treatment provides superior clinical outcomes, reducing:

• Duration of fever and illness symptoms
• Risk of complications
• Hospitalizations
• Death 1

While optimal benefit occurs within 48 hours, treatment initiated >48 hours after symptom onset still provides benefit in hospitalized or severely ill patients and should be strongly considered 1, 6

Resistance Patterns

• Do NOT use amantadine or rimantadine—high resistance levels exist 1
• Current circulating strains show sensitivity to oseltamivir, zanamivir, and peramivir 1
• Monitor local surveillance data for resistance patterns 1

Supportive Care

• Oxygen therapy for hypoxemia
• IV fluids for volume depletion
• Nutritional support in severe/prolonged illness
• Monitor vital signs, oxygen saturation, mental status at least twice daily (more frequently if severe) 7

Antibiotics: When to Add

Do NOT routinely prescribe antibiotics for uncomplicated influenza 7, 4

Consider antibiotics when:

• High-risk patients develop lower respiratory tract features
• Previously well patients develop worsening symptoms (recrudescent fever, increasing dyspnea)
• Evidence of bacterial superinfection (pneumonia) 7

Preferred choices:

• Co-amoxiclav or tetracycline (oral)
• IV co-amoxiclav or 2nd/3rd generation cephalosporin if oral contraindicated
• Macrolide or fluoroquinolone as alternative 7

What NOT to Use

Strong recommendations against:

• Corticosteroids (unless indicated for asthma/COPD exacerbation or septic shock)—observational data suggest harm 6, 4, 5
• Antibiotics for non-severe influenza without bacterial infection 4, 5
• NSAIDs, macrolides, mTOR inhibitors, convalescent plasma for severe cases 4, 5
• Double-dose oseltamivir—no benefit over standard dosing 1

Adverse Effects

Oseltamivir's main adverse effect is vomiting (15% vs 9% placebo in children) 1. Administering with meals improves GI tolerability 1, 2. Neuropsychiatric concerns from Japanese reports have not been substantiated in controlled trials 1.

Chemoprophylaxis Indications

Offer prophylaxis to:

• High-risk patients during the 2 weeks post-vaccination (before immunity develops) 8
• High-risk patients for whom vaccine is contraindicated or unavailable 8
• Unvaccinated household contacts of high-risk individuals 8
• All residents (vaccinated or not) during institutional outbreaks 8
• Anyone exposed to zoonotic influenza 4, 5

Duration: 10 days for seasonal influenza exposure; 7 days for institutional outbreaks 2